Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer

Departments of 1Radiation Oncology and 2Pathology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia; 3Cancer Research Institute; 4Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital; 5The Second Affiliated Hospital of Xiangya, Central South University, Changsha, Hunan, China

Departments of 1Radiation Oncology and 2Pathology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia; 3Cancer Research Institute; 4Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital; 5The Second Affiliated Hospital of Xiangya, Central South University, Changsha, Hunan, China

Departments of 1Radiation Oncology and 2Pathology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia; 3Cancer Research Institute; 4Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital; 5The Second Affiliated Hospital of Xiangya, Central South University, Changsha, Hunan, China

Departments of 1Radiation Oncology and 2Pathology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia; 3Cancer Research Institute; 4Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital; 5The Second Affiliated Hospital of Xiangya, Central South University, Changsha, Hunan, China

Departments of 1Radiation Oncology and 2Pathology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia; 3Cancer Research Institute; 4Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital; 5The Second Affiliated Hospital of Xiangya, Central South University, Changsha, Hunan, China

Departments of 1Radiation Oncology and 2Pathology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia; 3Cancer Research Institute; 4Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital; 5The Second Affiliated Hospital of Xiangya, Central South University, Changsha, Hunan, China

Departments of 1Radiation Oncology and 2Pathology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia; 3Cancer Research Institute; 4Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital; 5The Second Affiliated Hospital of Xiangya, Central South University, Changsha, Hunan, China

Departments of 1Radiation Oncology and 2Pathology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia; 3Cancer Research Institute; 4Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital; 5The Second Affiliated Hospital of Xiangya, Central South University, Changsha, Hunan, China

Departments of 1Radiation Oncology and 2Pathology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia; 3Cancer Research Institute; 4Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital; 5The Second Affiliated Hospital of Xiangya, Central South University, Changsha, Hunan, China